Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FEC-Taxotere/Vectibix in Breast Cancer
NCT00933517Phase 2Completed
- Sponsor
- Centre Jean Perrin
- Start
- Sep 2009
- Primary completion
- Oct 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in triple-negative breast cancer (TNBC), sponsored by Centre Jean Perrin. Started Sep 2009; status: completed.
02
Drugs
panitumumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00933517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00933517.